Halozyme Therapeutics, Inc. (HALO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Halozyme Therapeutics, Inc. (HALO) closed at USD 116.82 on 2026-10-14, a change of +78.6 % over the past year, with a market capitalization of USD 13.79B.

Halozyme Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Halozyme Therapeutics, Inc. key figures

Previous close

USD 116.82 (2026-10-14)

1-year change

+78.6 %

Market cap

USD 13.79B

Enterprise value

USD 15.74B

P/E ratio (trailing)

32.06

P/E ratio (forward)

11.38

EPS (trailing)

3.79

EPS (forward)

10.68

PEG ratio

n/a

Price to book

96.51

Revenue growth

47.7 %

Earnings growth

42.9 %

Dividend per share (trailing)

0.00

Short ratio

6.48

Employees

423

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Halozyme Therapeutics, Inc. and compare it with other stocks.